Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.
Spaulding Rehabilitation Hospital and Spaulding Research Institute, Charlestown, MA, USA.
Arch Clin Neuropsychol. 2021 Jan 15;36(1):126-134. doi: 10.1093/arclin/acaa044.
We examined the normative reference values, item-level symptom endorsement, internal consistency reliability, and the base rates of symptoms endorsed for the quality of life in neurological disorders (Neuro-QoL™) v2.0 Cognitive Function-Short Form.
The Neuro-QoL™ v2.0 Cognitive Function-Short Form measures subjective cognitive difficulties. The normative sample from the U.S. general population was stratified by gender, education, health status, self-reported diagnosis of depression or anxiety, and recent mental health symptoms (i.e., endorsed frequent anxiety or depression symptoms in the last week).
A cohort of 1,009 adults completed this scale and their mean score was 32.60 (SD = 6.89). The base rates of those who reported zero cognitive symptoms were consistently higher among the healthy samples (healthy men = 79.2%; all men = 63.9%; healthy women = 90.2%; all women = 80.0%). Endorsing three or more cognitive symptoms was more common in the mental health subgroups for both men (full men's sample [n = 493] = 17.6%; depression subgroup [n = 70] = 30.0%; anxiety subgroup [n = 61] = 29.5%; mental subhealth group [n = 70] = 38.6%) and women (full women's sample [n = 516] = 7.4%; depression subgroup [n = 123] = 13.0%; anxiety subgroup [n = 103] = 12.6%; mental health subgroup [n = 101] = 14.9%). Internal consistency was measured using Cronbach's α and ranged from 0.87 to 0.94 across groups.
The Neuro-QoL™ v2.0 Cognitive Function-Short Form is a brief, efficient, and reliable measure of perceived cognitive difficulties. As expected, individuals with a favorable overall health and quality of life reported less cognitive symptoms than the total sample, whereas individuals with mental health difficulties reported more. These normative values and base rates stratified by gender, overall health, and mental health status may be useful when interpreting this measure in clinical practice.
我们考察了生活质量在神经障碍中的神经评定量表（Neuro-QoL™）v2.0 认知功能简短型的常模参考值、项目水平症状的认可、内部一致性信度以及症状发生率。
Neuro-QoL™ v2.0 认知功能简短型测量主观认知困难。美国普通人群的常模样本按性别、教育程度、健康状况、自我报告的抑郁或焦虑诊断以及最近的心理健康症状（即过去一周经常出现焦虑或抑郁症状）进行分层。
共有 1009 名成年人完成了该量表，他们的平均得分为 32.60（SD=6.89）。在健康样本中，报告无认知症状的发生率始终较高（健康男性为 79.2%；所有男性为 63.9%；健康女性为 90.2%；所有女性为 80.0%）。在男性的心理健康亚组中，出现 3 个或更多认知症状的比例更高（全男性样本[n=493]为 17.6%；抑郁亚组[n=70]为 30.0%；焦虑亚组[n=61]为 29.5%；心理健康亚组[n=70]为 38.6%），在女性中也是如此（全女性样本[n=516]为 7.4%；抑郁亚组[n=123]为 13.0%；焦虑亚组[n=103]为 12.6%；心理健康亚组[n=101]为 14.9%）。内部一致性使用 Cronbach's α 进行测量，在各分组中范围为 0.87 至 0.94。
Neuro-QoL™ v2.0 认知功能简短型是一种测量感知认知困难的简短、高效、可靠的方法。正如预期的那样，整体健康和生活质量良好的个体比总样本报告的认知症状更少，而心理健康有困难的个体报告的认知症状更多。这些按照性别、整体健康状况和心理健康状况分层的常模值和发生率可能有助于在临床实践中解释该量表。
